Home > Publications database > Association of F2-isoprostane levels with Alzheimer's disease in observational studies: a systematic review and meta-analysis. > print

001     178311
005     20240229133804.0
024 7 _ |a 10.1016/j.arr.2021.101552
|2 doi
024 7 _ |a pmid:34954419
|2 pmid
024 7 _ |a 1568-1637
|2 ISSN
024 7 _ |a 1872-9649
|2 ISSN
024 7 _ |a altmetric:119746067
|2 altmetric
037 _ _ |a DKFZ-2021-03258
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Trares, Kira
|0 P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea
|b 0
|e First author
|u dkfz
245 _ _ |a Association of F2-isoprostane levels with Alzheimer's disease in observational studies: a systematic review and meta-analysis.
260 _ _ |a Oxford [u.a.]
|c 2021
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1641066104_10897
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C070#LA:C070#
520 _ _ |a The association between F2-isoprostanes and Alzheimer's disease (AD) has been controversially discussed in the literature since the 1990s. However, no systematic review has been performed so far.A systematic review of observational studies on the associations of F2-isoprostanes and the specific biomarker 8-iso-prostaglandin F2α with AD were conducted. Random-effects model meta-analyses were performed.29 studies were included in the systematic review, including four longitudinal studies. In an overall meta-analysis of the 25 cross-sectional studies, F2-isoprostane levels were statistically significantly associated with AD (Hedge's g [95% confidence interval]: 1.00 [0.69-1.32]). When studies were grouped by biomarker and sample specimen, F2-isoprostane and 8-iso-prostaglandin F2α levels were statistically significantly elevated in tissue samples of the frontal lobe of AD patients. Moreover, F2-isoprostane levels in cerebrospinal fluid and 8-iso-prostaglandin F2α levels in blood samples of AD patients were significantly increased. Meta-analyses of the few longitudinal studies did not reach statistical significance.Increased concentrations of F2-isoprostanes were found in AD patients. However, due to the lack of adjustment in most cross-sectional case-control studies, results must be interpreted carefully. In addition, the causality of the association is uncertain because evidence from well-conducted longitudinal studies was conflicting, and further longitudinal studies are required to reinforce the results.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a 8-iso-prostaglandin F(2α)
|2 Other
650 _ 7 |a Alzheimer’s Disease
|2 Other
650 _ 7 |a F(2)-isoprostanes
|2 Other
650 _ 7 |a Observational studies
|2 Other
650 _ 7 |a Oxidative stress
|2 Other
650 _ 7 |a Systematic review
|2 Other
700 1 _ |a Chen, Li-Ju
|0 P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe
|b 1
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 2
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.arr.2021.101552
|g Vol. 74, p. 101552 -
|0 PERI:(DE-600)2099320-1
|p 101552
|t Ageing research reviews
|v 74
|y 2021
|x 1568-1637
909 C O |o oai:inrepo02.dkfz.de:178311
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AGEING RES REV : 2019
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-30
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b AGEING RES REV : 2019
|d 2021-01-30
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21